新人999女性脂溢性脱发如何治疗配图，仅供参考
The following are several options available for systemic treatment. Hormone-related treatments are commonly used for male and female androgenetic alopecia. Finasteride,a type II 5-alpha reductase inhibitor,is effective for male androgenetic alopecia,but its use in female androgenetic alopecia is limited due to potential teratogenic effects. Recent studies evaluated the role of finasteride in the treatment of FPHL in more detail. The results showed that topical finasteride may be used as a new option to reduce adverse systemic side effects . Whereas dutasteride,a second-generation 5-alpha reductase inhibitor,is more effective than finasteride,further studies are needed to determine its safety and effectiveness in female androgenetic alopecia . Cyproterone acetate is an anti-androgen still without a consensus on dosage for female androgenetic alopecia. Indeed,there is insufficient evidence on whether oral hormone therapy prevents or improves FPHL. Spironolactone is an off-label use for female androgenetic alopecia and has a good safety profile. Clinical studies suggest a daily dose of 100–200 mg,with the best response after 1 year or more of treatment . On the other hand,oral Minoxidil is not a preferred first-line treatment for FPHL due to its higher incidence of side effects compared to topical Minoxidil. In a randomized clinical trial involving 52 FPHL patients,oral Minoxidil (1 mg per day) and Minoxidil 5% solution once a day showed no significant difference in treatment outcomes such as hair density,but side effects were more significant in the oral Minoxidil group (27%) than the topical Minoxidil group (4%) . Currently,a low dose of 0.25 mg is commonly used for FPHL patients who receive oral Minoxidil .","department":"
